Diesen Newsletter in Deutsch anzeigen.
Nächsten Newsletter in Deutsch erhalten? Antworten Sie uns bitte mit "Sprache wechseln".
 
  Business Association Chemistry Pharma Biotech
 
Newsletter
January 15th, 2014
    To whom it may concern

scienceindustries, the Swiss Business Association Chemistry Pharma Biotech, keeps you informed about our industry's standpoints on current politico-economic and social topics.
 
 
Topics
in this Issue
   
Don't jeopardize bilateral contracts – say NO to the «Mass immigration initiative»  
 
Free trade agreement with India: No agreement without controls on the importation of patent-protected products  
 
Pharma Cooperation Code and revised Pharma Code in force from 2014  
 
«Energy strategy 2050»: Transition from promotion system to control system  
 
«No» to the integration of REACH into the Swiss Chemicals Act  
 
Swiss export risk insurance SERV: «Yes» to partial overhaul  
 
New scienceindustries platform on the subject of crop protection  
 
PG BFI session event: «Best Talents: For a competitive Switzerland»  

 
 
      Don't jeopardize bilateral contracts – say NO to the «Mass immigration initiative»

Eligible voters will cast their votes on the SVP's «Mass immigration initiative» on 9th February 2014. This initiative demands that annual maximum numbers should be introduced for all immigrants, cross-border commuters and asylum seekers. As a «Yes» vote to the initiative would contravene the agreement with the EU on the free movement of people, the adoption of this initiative would have far-reaching consequences. Withdrawal from the EU agreement would make all six agreements contained in Bilateral Package I obsolete (including the agreement on technical trade barriers and research collaboration). scienceindustries therefore recommends a NO vote on the SVP isolation initiative on 9th February 2014.
 
 
      Free trade agreement with India: No agreement without controls on the importation of patent-protected products

Switzerland is currently working within EFTA to negotiate a free trade agreement with India. scienceindustries calls for a trade agreement that recognises the importation of a patent-protected product as the exercise of the patent. Up to now, India has required that the holders of foreign patents should manufacture locally within India. This is equivalent to a protectionist isolation of its market, which contradicts the spirit of any free trade agreement and international obligations under TRIPS. Any trade agreement that does not include adequate protection of intellectual property would represent a devastating signal for Switzerland as a research and production location, and would endanger future investments in research and development. In addition, this would also create a dangerous precedent with regard to other current and planned free trade agreements. The disadvantages produced by the lack of protection for intellectual property would also heavily outweigh the benefits of the reduction in customs duties. From scienceindustries' point of view, therefore, it is more important to reach an agreement of high quality than to reach an agreement quickly.
 
 
      Pharma Cooperation Code and revised Pharma Code in force from 2014

During the past year, the European Federation of Pharmaceutical Industries and Associations, EFPIA, has adopted the «EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations». According to this code, pharmaceuticals companies must disclose all payments, particularly any payments made to doctors and hospitals. This annual duty of publication will apply from 2016; the payments made in 2015 will be the first to be covered by this provision. At the same time, the Annual General Meeting of EFPIA also revised the «EFPIA Code of Practice on the promotion of prescription-only medicines to, and interactions with, healthcare professionals». In line with this revision, pharmaceuticals companies will be fundamentally forbidden to give gifts to specialists, particularly doctors, from mid-2014 onwards. These EFPIA Codes will be implemented by the national industry associations. scienceindustries will be responsible for this in Switzerland, and, in co-ordination with its partner associations, it has prepared the new Pharma Cooperation Code and revised the existing Pharma Code for this purpose. Both these codes have been in effect since 1st January 2014.
 
 
      «Energy strategy 2050»: Transition from a promotion system to a control system

scienceindustries fundamentally rejects an actual ecological tax reform because of the goal conflict between the control targets for the deduction and its financing targets. In its report on «The transition from a promotion system to a control system» the Swiss Federal Department of Finance suggests two versions of a transition towards a control system. In both versions, the revenues would be reimbursed to households and businesses after deducting the earmarked funds. While scienceindustries supports emissions-oriented control deductions as a replacement for «command and control» environmental regulation, as long as the deductions fulfil the requirements of scienceindustries' 7-point programme, it is sceptical about resource-oriented deductions. These cannot be understood as a fundamental regulatory correction for a failure of the market.
 
 
      «No» to the integration of REACH into the Swiss Chemicals Act

The EU's REACH Chemicals legislation has already had an effect on Swiss companies who export more than a ton of materials and preparations into the EU every year. scienceindustries rejects the adoption of REACH in Switzerland and any corresponding bilateral agreement with the EU on REACH. Adoption of REACH into Swiss law would produce only marginal administrative simplifications, but would lead to considerable disadvantages such as the requirement for a duty of notification for non-traded intermediates. The retention of the applicable Swiss Chemicals Act ensures enough safety provisions and is already sufficiently harmonised with REACH. More information about REACH is available for our members on the scienceindustries Membernet (in german).
 
 
      Swiss export risk insurance SERV: «Yes» to partial overhaul

In its reply to the relevant Swiss Federal legislative process by consultation, scienceindustries supports the anticipated definitive introduction of the manufacturing credit insurance, the bond guarantee and the refinancing guarantee. However, these extensions of the range currently on offer must not damage SERV's own economic efficacy on an ongoing basis and must not trigger any substantial cross subsidisation between the options. scienceindustries also welcomes the change from global insurance policies to the provision of guarantees in the form of dispositions. This instrument is administratively easy and has proved its worth with the export risk guarantee. scienceindustries also supports the introduction of a discretionary regulation in place of the exception clause for export transactions with a Swiss value added proportion of less than 50%.
 
 
      New scienceindustries platform on the subject of crop protection

Over the past few years, the underlying conditions governing the use of crop protection products in Switzerland and the EU have worsened significantly as a result of political campaigns based around the subject of bee health. The use of a series of crop protection products from the neonicotinoid group has been prohibited in the absence of any evidence of a connection with the death of bees. On the basis of the previous activities of the Agrar group, scienceindustries resolved in October 2013 to intensify activities involving the affected member companies in this area with the aim of undertaking more explanatory work in the political, public and media areas. One important aspect of this issue involves residues in water, which could also affect other products from our industries in future.
 
 
      PG BFI session event: «Best Talents: For a competitive Switzerland»

On 26th September 2013, almost two dozen national politicians from Switzerland's parliamentary group on education, research and innovation, known as PG BFI and initiated by scienceindustries, came together under the chairmanship of Swiss National Council Member Gerhard Pfister to learn more from Dr. Thomas Bösch, Head of HR Novartis Switzerland, and Pascal Brenneisen, Country Head Novartis Switzerland, on the subject of «Best Talents: For a competitive Switzerland». Once again, this event proved that a direct exchange of views between the members of Switzerland's National Council and Council of States and representatives from the Chemistry Pharma Biotech industries is very much appreciated.
 
 
     
Would you like to know more about our perspectives, or would you like to ask us some questions? If so, please contact our specialist staff at scienceindustries.

sig. Dr. Beat Moser
Director
sig. Marcel Sennhauser
Communication
 
 
      scienceindustries
Business Association Chemistry Pharma Biotech
Nordstrasse 15 - P.O. Box
CH-8021 Zurich
Phone +41 44 368 17 11
Fax +41 44 368 17 70
E-Mail info@scienceindustries.ch
Internet www.scienceindustries.ch
 
   
  ©2014 scienceindustries | Impressum